Johnson & Johnson (NYSE:JNJ - Get Free Report) was upgraded by equities researchers at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm presently has a $212.00 target price on the stock. Wells Fargo & Company's price target indicates a potential upside of 12.46% from the company's previous close.
Other equities analysts have also issued reports about the stock. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Bank of America raised their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a research report on Friday. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Finally, UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $187.47.
View Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $188.51 on Friday. The firm has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm's 50 day moving average is $176.18 and its two-hundred day moving average is $162.83.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Insider Buying and Selling at Johnson & Johnson
In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Johnson & Johnson
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HCR Wealth Advisors lifted its holdings in Johnson & Johnson by 13.0% in the third quarter. HCR Wealth Advisors now owns 11,633 shares of the company's stock valued at $2,164,000 after acquiring an additional 1,341 shares during the period. Summit Financial Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 11.9% in the third quarter. Summit Financial Wealth Advisors LLC now owns 7,246 shares of the company's stock valued at $1,348,000 after acquiring an additional 768 shares during the period. Aaron Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 72.1% in the third quarter. Aaron Wealth Advisors LLC now owns 35,832 shares of the company's stock valued at $6,644,000 after acquiring an additional 15,006 shares during the period. First Citizens Financial Corp lifted its holdings in Johnson & Johnson by 9.7% in the third quarter. First Citizens Financial Corp now owns 7,181 shares of the company's stock valued at $1,332,000 after acquiring an additional 636 shares during the period. Finally, IMPACTfolio LLC acquired a new stake in Johnson & Johnson in the third quarter valued at $254,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
